IDEBENONE COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
The invention describes the use of an injectable form of Idebenone to induce protect from neuronal damage, improve recovery after brain trauma; stroke, intoxication, neurodegenerative diseases, memory loss or neuropathology associated with neuroinflammation or infection damage and to restore cognitive function, suppress disorientation, alcoholic and drug abuse associated syndromes and other signs of neuronal damage.
1 . A method of treatment of neurological disorders and improving conditions associated with neuronal damage by parenteral administration of a neuroprotective pharmaceutical composition, comprising of at least one physiologically acceptable derivative of 1,4-benzoquinone.
2 . A method as set forth in claim 1 wherein said derivative is 1,4-benzoquinone is 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone).
3 . A method as set forth in claim 1 wherein said composition is administrated parenterally via intravenous injection, intravenous infusion, intra-arterial, intramuscular, subcutaneous or intraperitoneal injection.
4 . A method as set forth in claim 1 wherein said derivative of 1,4-benzoquinone is administrated in dosage concentrations of 0.5 to 50 mg/kg per day.
5 . A method as set forth in claim 1 wherein said composition is a colloidal delivery system, elected from micellar preparations, emulsions, solid lipid nanoparticles, polymeric anoparticles, nanocapsules or suspensions, wherein said 1,4-benzoquinone derivative is associated with the hydrophobic phase of the colloidal system.
6 . A method as set forth in claim 5 wherein said emulsion is an oil-in-water emulsion.
7 . A method as set forth in claim 1 wherein said neurological disorder is caused by Neurotrauma.
8 . A method as set forth in claim 1 wherein said neurological disorder is stroke.
9 . A method as set forth in claim 1 wherein said neurological disorder is encephalomyelitis.
10 . A method as set forth in claim 1 wherein said neurological disorder is associated with mitochondrial dysfunction.
11 . A method as set forth in claim 1 wherein said neurological disorder is associated with an hypoxic condition.
12 . A method as set forth in claim 1 wherein said neurological disorder is alcohol withdrawal syndrome or fetal alcoholic syndrome.
13 . A method as set forth in claim 1 wherein said neurological disorder is associated with neuronal damage caused by bacterial or viral infection.